Drug Monograph

Drug Name: **Mavyret® (glecaprevir/pibrentasvir) oral pellets**
Drug Class: **Anti-Infectives: Hepatitis C Agents, Oral Direct-Acting Antivirals**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Mavyret is now available as in unit-dose packets each containing 50 mg glecaprevir/20 mg pibrentasvir oral pellets.
Manufacturer:	Manufactured by: AbbVie Inc., North Chicago, IL 60064.
Indications:	Mavyret is indicated for the treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). Mavyret is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NSSA inhibitor or an NS3/4A protease inhibitor (PI), but not both.
Costs:	$2,640.12 per 28 packets. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL)
Status Recommendation:	☐ Clinical Edit ☐ PA Required ☐ Open Access ☒ PDL
Type of PA Criteria:	☐ Appropriate Indications ☐ Non-Preferred ☐ No PA Required ☒ Preferred

Prepared by: April Ash, PharmD
Date: December 30, 2021